Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
Zofia Piotrowska(Global Cancer Institute), Catherine A. Shu(Columbia University Irving Medical Center), Cathleen Park(University of California, Davis), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Misha C. Tran, Stephen V. Liu(Georgetown University), Susan C. Scott(Johns Hopkins University), Jennifer A. Marks(Dana-Farber Cancer Institute), Kristen A. Marrone(Johns Hopkins University), Mandeep K. Banwait(Massachusetts General Hospital), Richard D. Hall(University of Virginia Health System), Elaine Shum(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Lanyi Nora Chen(Columbia University Irving Medical Center), Matthew Guo(Johns Hopkins University), Ying Liu(Chongqing University), Ryan D. Gentzler(University of Virginia Health System)
Cited by 9
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k